格隆汇5月29日丨领航医药生物科技(00399.HK)公告,于2025年5月29日,公司与配售代理订立配售协议,据此,配售代理已有条件同意担任公司代理,以竭诚促使目前预期不少于六名承配人(彼等及其最终实益拥有人应为独立第三方)按每股配售股份0.175港元的配售价认购最多206,400,000股配售股份。假设公司已发行股本于本公告日期至完成配售事项日期期间不会有变,最多206,400,000股配售...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.